Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00731900

Enrollment

100

Registered

2008-08-11

Start date

2007-04-30

Completion date

2009-12-31

Last updated

2008-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction

Keywords

pharmacogenetic, study, Topirmate, induced

Brief summary

Topiramate (TPM) is an antiepileptic drug with a unique mode of action that is often useful in patients refractory to other drugs. However its use is restricted by the high incidence of cognitive adverse drug reactions (ADRs) that are associated with TPM exposure. TPM has been shown to cause particular cognitive ADRs, characterized by verbal fluency, attention, working memory and language deficits, at a much higher rate than other antiepileptic drugs. There do not appear to be obvious differences between patients that do or do not experience cognitive ADRs when on TPM (e.g. age, sex, concomitant medications, diagnosis), which suggests a genetic contributor.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

17 Years to 70 Years

Healthy volunteers

Inclusion criteria

* adult (\>17 years old) patients with epilepsy or patients with migraine treated by topiramate

Exclusion criteria

* allergy to topiramate * abnormal liver or renal function

Countries

Taiwan

Contacts

Primary ContactHorng-Huei Liou, MD;PhD

hhl@ntu.edu.tw886-2-23123456

Outcome results